Marimastat was a proposed
antineoplastic drug developed by
British Biotech. It acted as a broad-spectrum
matrix metalloproteinase inhibitor
A matrix metalloproteinase inhibitor (MMPI) inhibits matrix metalloproteinases. As they inhibit cell migration
Cell migration is a central process in the development and maintenance of multicellular organisms. Tissue formation during embryonic d ...
.
Marimastat performed poorly in clinical trials,
and development was terminated. This may be, however, a result of targeting cancer at too late of a stage. This is supported by the fact that MMP inhibitors have more recently been shown in animal models to be more effective in earlier stages of cancers. (Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812. Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D. (1999)).
See also
*
Batimastat
References
Experimental cancer drugs
Hydroxamic acids
Matrix metalloproteinase inhibitors
{{antineoplastic-drug-stub